
Report on BioNTech Africa: more needed to achieve sustainable regional production of medicines
The BioNTech mRNA vaccine manufacturing facility in Rwanda contributes to greater access to mRNA vaccines in Africa in the short-term, but it lacks plans and commitments to enhance sovereignty and self-reliance of the continent in access to health products in the long-term. This is the main conclusion from a case study of the BioNTech Africa facility, conducted by four public health NGOs from Africa and Europe, including Wemos. Read more